{'fraction_non_alphanumeric': 0.03977272727272727, 'fraction_numerical': 0.008522727272727272, 'mean_word_length': 5.778846153846154, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Bioactive Steroid Marinobufagenin in a Mouse Model of Early‐Stage Alzheimer's Disease

Alzheimer’s disease (AD) is characterized by brain amyloid beta plaque formation, neuroinflammation and neuronal degradation, which lead to cognitive impairment and decline in normal circadian rhythm (CR). Bioactive steroid marinobufagenin (MBG) modulates neuroinflammation. In 16‐mo old double transgenic APPswe/PS1dE9 AD mice with advanced AD, amyloid precursor protein (APP) and interleukin 6 (IL6) mRNAs were upregulated vs. wild type (WT) control, and treatment with MBG reduced mRNA expression. Here, we investigated whether treatment with MBG at early‐stage AD may impact AD development in this AD mouse model.